Open AccessSignificance of Monoclonal PCSK9-Antibodies - New Approaches to the Therapy of Hypercholesterolemia
Author(s) -
Claas Lennart Neumann,
Elke Schettler,
Volker Schettler
Publication year - 2016
Publication title -
blood purification
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.686
H-Index - 57
eISSN - 1421-9735
pISSN - 0253-5068
DOI - 10.1159/000443140
Subject(s) - pcsk9 , kexin , ldl receptor , monoclonal antibody , lipoprotein , medicine , proprotein convertase , low density lipoprotein , cholesterol , monoclonal , familial hypercholesterolemia , antibody , endocrinology , pharmacology , immunology
Increased concentrations of low-density-lipoprotein (LDL)-cholesterol (LDL-C) and lipoprotein a (Lp(a)) are scientifically accepted, independent risk factors for the development of atherosclerosis. The complications of atherosclerosis occur early and more frequently. They are strongly linked with lifestyle factors and an increase of LDL-C concentrations in industrialized countries. A new therapeutic approach seems to be the modulation of the proprotein convertase subtilisin/kexin type 9 (PCSK9), which reduces the number of LDL-receptors at the cell membrane of the liver cells and thus increases the concentration of LDL-C in the blood. Results of current studies show, that in particular, a combination of PCSK9-AB and statins, independent of the dosage of the statins, is suitable to increase a reduction of LDL-C and Lp(a). This article gives an overview of the pathophysiology, the current study and research situation as well as the possible different approaches to the therapeutic influence of PCSK9 in the future.